SCHEMBL3335832

SCHEMBL3335832

Nc1nc(OCCN2CCOCC2)c2cc(-c3ccc(Cl)c(C(F)(F)F)c3)ccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.47
BRAF P15056 1/20 0.47
RAF1 P04049 1/20 0.43
ACHE P22303 2/20 0.42
BCHE P06276 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PIK3CA P42336 2/20 0.42
KMO O15229 3/20 0.41
TSHR P16473 2/20 0.41
KDR P35968 1/20 0.41
ADORA2A P29274 2/20 0.41
ADORA1 P30542 2/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336925 0.85 CYP1A2 (0.57) ACHEBCHEMAOAMAOBALDH1A1
SCHEMBL3337374 0.84 MEN1 (0.47) MAPK14ACHEBCHEMAOAMAOB
SCHEMBL3334174 0.84 ADORA2A (0.54) MAPK14ACHEBCHEMAOAMAOB
SCHEMBL3338145 0.82 ACHE (0.47) ACHEBCHEMAOAMAOBHSP90AA1
SCHEMBL3337443 0.81 NOTUM (0.38) MAPK14BRAFRAF1HSP90AB1KDM4E
SCHEMBL3336155 0.80 CYP1A2 (0.54) ACHEBCHEMAOAMAOBHSP90AA1
SCHEMBL3340207 0.79 KIT (0.55) ACHEBCHEMAOAMAOBKDM4E
SCHEMBL3339832 0.79 HRH1 (0.45) ACHEBCHEMAOAMAOBHSP90AA1
SCHEMBL3334078 0.79 KMT2A (0.48) ACHEBCHEMAOAMAOBALDH1A1
SCHEMBL3339040 0.77 ALDH1A1 (0.48) ACHEBCHEMAOAMAOBHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 MAPK14 2920/4885BRAF 2516/4885RAF1 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.